Figure 5.
Estimated cumulative incidence of the proportion of patients with relapse/PD and NRM over time. Relapse/PD and NRM in the overall population (A) and BTKi (B), number of prior therapy lines (C), and bendamustine (D) subgroups. Vertical dashed lines indicate 6- and 12-month landmarks.

Estimated cumulative incidence of the proportion of patients with relapse/PD and NRM over time. Relapse/PD and NRM in the overall population (A) and BTKi (B), number of prior therapy lines (C), and bendamustine (D) subgroups. Vertical dashed lines indicate 6- and 12-month landmarks.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal